Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
22 July 2023 - 12:20AM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
hereditary angioedema (HAE) attacks, today shared data from the
RAPIDe-1 Phase 2 clinical study of PHVS416 (deucrictibant
immediate-release capsules) for the on-demand treatment of HAE
attacks, including data focused on time-to-symptom relief and
resolution of HAE attacks, in two poster presentations at the 2023
U.S. HAEA National Summit, taking place in Orlando, Florida from
July 20-23.
Presentation details:
- Title: Efficacy and safety of bradykinin B2
receptor antagonism with deucrictibant immediate-release capsule
for treatment of hereditary angioedema attacks: results of RAPIDe-1
phase 2 trialPresenter: Marc A. Riedl, M.D.,
M.S.Poster ID: #6
- Title: Treatment with oral bradykinin B2
receptor antagonist deucrictibant immediate-release capsule
improves hereditary angioedema attack
symptomsPresenter: John Anderson,
M.D.Poster ID: #26
The presentations will take place in the hallway outside of the
Professional-Scientific Track room, Gatlin A2/A3, at Rosen Shingle
Creek in Orlando, on Friday, July 21, from 9:50-10:20 a.m. EDT. The
posters will be available for viewing from Friday, July 21, at 7:45
a.m. EDT to Saturday, July 22, at 12:30 p.m. EDT, and will be made
publicly available on the Investors section of the Pharvaris
website at:
https://ir.pharvaris.com/news-events/events-presentations.
About PharvarisBuilding on its deep-seated
roots in HAE, Pharvaris is a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
HAE attacks. By directly targeting this clinically proven
therapeutic target with novel small molecules, the Pharvaris team
aspires to offer people with all sub-types of HAE safe, effective,
and convenient alternatives to treat attacks, both on-demand and
prophylactically. The company brings together the best talent in
the industry with deep expertise in rare diseases and HAE. For more
information, visit https://pharvaris.com/.
Forward-Looking StatementsThis press release
contains certain forward-looking statements that involve
substantial risks and uncertainties. All statements contained in
this press release that do not relate to matters of historical fact
should be considered forward-looking statements, including, without
limitation, statements relating to the Offering and the use of
proceeds therefrom, and any statements containing the words
“believe,” “anticipate,” “expect,” “estimate,” “may,” “could,”
“should,” “would,” “will,” “intend” and similar expressions. These
forward-looking statements are based on management’s current
expectations, are neither promises nor guarantees, and involve
known and unknown risks, uncertainties and other important factors
that may cause Pharvaris’ actual results, performance or
achievements to be materially different from its expectations
expressed or implied by the forward-looking statements. Such risks
include but are not limited to the following: uncertainty in the
outcome of our interactions with regulatory authorities, including
the FDA with respect to the clinical hold on prophylactic
deucrictibant in the U.S.; the expected timing, progress, or
success of our clinical development programs, especially for
PHVS416 (immediate-release deucrictibant capsules) and PHVS719
(extended-release deucrictibant tablets), which are in mid-stage
global clinical trials; risks associated with the COVID-19
pandemic, which may adversely impact our business, nonclinical
studies, and clinical trials; the timing of regulatory approvals;
the value of our ordinary shares; the timing, costs and other
limitations involved in obtaining regulatory approval for our
product candidates PHVS416 and PHVS719, or any other product
candidate that we may develop in the future; our ability to
establish commercial capabilities or enter into agreements with
third parties to market, sell, and distribute our product
candidates; our ability to compete in the pharmaceutical industry
and with competitive generic products; our ability to market,
commercialize and achieve market acceptance for our product
candidates; our ability to raise capital when needed and on
acceptable terms; regulatory developments in the United States, the
European Union and other jurisdictions; our ability to protect our
intellectual property and know-how and operate our business without
infringing the intellectual property rights or regulatory
exclusivity of others; our ability to manage negative consequences
from changes in applicable laws and regulations, including tax
laws, our ability to successfully remediate the material weakness
in our internal control over financial reporting and to maintain an
effective system of internal control over financial reporting;
changes in general market, political and economic conditions,
including as a result of the current conflict between Russia and
Ukraine; and the other factors described under the headings
“Cautionary Statement Regarding Forward-Looking Statements” and
“Item 3. Key Information—D. Risk Factors” in our Annual Report on
Form 20-F and other periodic filings with the U.S. Securities and
Exchange Commission. These and other important factors could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. New risks and uncertainties may
emerge from time to time, and it is not possible to predict all
risks and uncertainties. While Pharvaris may elect to update such
forward-looking statements at some point in the future, Pharvaris
disclaims any obligation to do so, even if subsequent events cause
its views to change. These forward-looking statements should not be
relied upon as representing Pharvaris’ views as of any date
subsequent to the date of this press release.
Contact
Maggie Beller
Head of Public Relations and Communications
Maggie.beller@pharvaris.com
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Jul 2023 to Jul 2024